मिटापिवैट और नॉरएथिस्टेरोन का इंटरैक्शन

Sensitive CYP3A substrates including hormonal contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.

Avoid concomitant use with hormonal contraceptives except for intrauterine systems containing levonorgestrel.

Co-administration of AQVESME will decrease systemic concentrations of drugs that are sensitive CYP3A substrates, including hormonal contraceptives (e.g., ethinyl estradiol) [see Clinical Pharmacology (12.3) ] .

If contraception is desired or needed, use an alternative contraceptive that is not affected by enzyme inducers.

Counsel women to use an alternative non-hormonal method of contraception or a back-up method when enzyme inducers are used with HCs, and to continue back-up non-hormonal contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability.